{"id":17627,"date":"2025-02-05T21:44:44","date_gmt":"2025-02-05T14:44:44","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=17627"},"modified":"2025-02-05T21:44:44","modified_gmt":"2025-02-05T14:44:44","slug":"ai-genomics-advances-bring-new-hope-to-lung-cancer-burden-in-asia","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=17627","title":{"rendered":"AI & Genomics Advances Bring New Hope to Lung Cancer Burden in Asia"},"content":{"rendered":"

SINGAPORE<\/span><\/span>, Feb. 5, 2025<\/span><\/span> \/PRNewswire\/ — Asia<\/span> is the region most impacted by lung cancer, accounting for 63.1% of newly diagnosed lung cancers and 62.9% of lung cancer deaths worldwide(1)<\/sup>.<\/p>\n

Many countries have applied low-dose CT scans to screen for this deadly cancer to improve early detection and treatment outcomes. However, only the highest-risk population (heavy smokers) is advised to undergo low-dose CT scans routinely to minimize the risk of radiation-induced cancer during scanning rounds(2)<\/sup>. Moreover, CT devices are not easily accessible for many people due to geographical and economic barriers.<\/p>\n

Due to these limitations, multiple studies have pointed out surprising data: the current screening guidelines and eligibility criteria may miss over 50% of lung cancer cases in never-smokers(3)<\/sup>; women are particularly vulnerable, with 83% of women in South-East Asia<\/span> with lung cancer being never-smokers(4)<\/sup>; non-smokers are diagnosed at a later stage than smokers (5)<\/sup>; and about a third of lung cancer deaths occur in non-smokers(6)<\/sup>.<\/p>\n

New screening method leveraging AI and genomics technology advantages<\/b>\u00a0<\/p>\n

SPOT-MAS is a blood test developed by Gene Solutions to detect multiple features of circulating tumor DNA (ctDNA) released from cancer cells, indicating if someone may have cancer. Previously, SPOT-MAS was validated as a multi-cancer early detection test in a longitudinal study involving 9,024 healthy people. While detecting multiple cancers, including lung cancer, in a single blood test is an aspirational goal, the key challenge lies in making it affordable for a large population.<\/p>\n

To address this challenge, Gene Solutions integrates a multiomics tumor ATLAS with AI-driven feature engineering and deep learning models<\/a>\u00a0to analyze genetic, epigenetic, and fragmentomic data. This methodology offers a precise, non-invasive, and affordable test specifically designed for lung cancer screening. Through enhanced AI analysis and the incorporation of lung-specific features, the SPOT-MAS Lung test has demonstrated remarkable effectiveness, achieving 90% sensitivity and 92% specificity(7)<\/sup>.<\/p>\n

A new hope for lung cancer burden in Asia<\/span><\/b><\/p>\n

With extensive connections to healthcare providers across Asia<\/span>, Gene Solutions aims to introduce this smart blood test to clinical practice in early 2025 to support the urgent need for accessible lung screening. In the long run, a convenient and precise test like SPOT-MAS can increase the chances of early detection for at-risk populations and potentially reduce the mortality rate associated with late diagnoses.<\/p>\n

Furthermore, ctDNA screening tests can serve as a companion tool to low-dose CT scans<\/span><\/a>.\u00a0<\/span>In real-life practice, many CT scans yield ambiguous results, such as small lung nodules classified under LUNG-RADS (8)<\/sup>, which might leave clinicians and patients uncertain about the malignancy status and the appropriate follow-up surveillance path. ctDNA screening results can thus support and guide diagnosis and surveillance strategies.<\/p>\n

At the January\u00a0event Personalized cancer care in Asia<\/span>: Advancing Genomics & AI in Singapore<\/span>, Dr. Nguyen Hoai Nghia<\/span>, Founder of Gene Solutions,\u00a0highlighted: “This technology represents a paradigm shift in lung cancer screening, particularly for underserved\u00a0populations.<\/b> By harnessing the power of ctDNA and AI, we aim to make blood-based cancer screening tests more accurate and more affordable, hence support more early detection and effective treatment outcomes.”\u00a0<\/p>\n

\n

Dr. Nguyen Hoai Nghia announced the performance of the SPOT-MAS Lung test at the event \"Personalized Cancer Care in Asia: Advancing Genomics & AI\" at SGX Auditorium, Singapore, January 2025.<\/a>
Dr. Nguyen Hoai Nghia announced the performance of the SPOT-MAS Lung test at the event “Personalized Cancer Care in Asia: Advancing Genomics & AI” at SGX Auditorium, Singapore, January 2025.<\/span><\/p>\n<\/div>\n

About\u00a0Gene Solutions
<\/b>Gene Solutions, a pioneering biotech company in Asia<\/span>, is leading the way in leveraging advanced AI and ctDNA technologies for innovative cancer detection solutions. The company partners with over 4,500 hospitals and clinics across Southeast Asia<\/span> and boasts a team of approximately 250 biology experts and technicians out of a total of 700 employees. Gene Solutions has published more than 50 peer-reviewed publications and conducted over 50 multi-center studies across the region. The company, recognized for its proprietary research and CAP-accredited laboratories in Singapore<\/span> and Vietnam<\/span>, combines multi-dimensional genomics with AI-driven approaches to transform cancer care.\u00a0<\/p>\n

For media inquiries, please contact: Gene Solutions Media Contact\u00a0
Ms. Emma Ngo<\/span><\/b>\u00a0
www.genesolutions.com<\/a><\/u>\u00a0
Email: pr@genesolutions.com<\/a><\/b>\u00a0<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

References:<\/b>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(1)<\/sup> <\/i>Chiu, C., & Yang, P. (2024). Challenges of lung cancer control in Asia. EClinicalMedicine, 74, 102706. doi.org\/10.1016\/j.eclinm.2024.102706<\/i>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(2)<\/sup> <\/i>Pozzessere, C.; von Garnier, C.; Beigelman-Aubry, C. Radiation Exposure to Low-Dose Computed Tomography for Lung Cancer Screening: Should We Be Concerned? Tomography 2023, 9, 166-177. doi.org\/10.3390\/tomography9010015<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(3)<\/sup> <\/i>Kerpel-Fronius, A., Tammem\u00e4gi, M., Cavic, M., Henschke, C., Jiang, L., Kazerooni, E., Lee, C., Ventura, L., Yang, D., Lam, S., Huber, R. M., Yang, D., Zulueta, J., Viola, L., Mohan, A., Lee, C., Cavic, M., Schmidt, H., Kazerooni, E., . . . Huber, R. (2021). Screening for lung cancer in Individuals who Never smoked: An International Association for the Study of Lung Cancer Early Detection and Screening Committee report. Journal of Thoracic Oncology, 17(1), 56\u201366. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.031<\/a><\/u><\/i>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(4)<\/sup> <\/i>Barta, J. A., Powell, C. A., & Wisnivesky, J. P. (2019). Global Epidemiology of Lung Cancer. Annals of Global Health, 85(1). https:\/\/doi.org\/10.5334\/aogh.2419<\/i>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(5)<\/sup> Barta JA, et al. Global Epidemiology of Lung Cancer. Annals of Global Health. (2019). 85(1): 8, 1\u201316. DOI: https:\/\/doi. org\/10.5334\/aogh.2419<\/i>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(6)<\/i><\/sup>\u00a0GLOBOCAN (2020).\u00a0<\/i>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(7)<\/sup> Nguyen, Van Thien Chi et al. Cost-Effective Shallow Genome-Wide Sequencing for Profiling Plasma cfDNA Signatures to Enhance Lung Cancer Detection (January 11, 2025). dx.doi.org\/10.2139\/ssrn.5094108<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(<\/i>8<\/i><\/sup>)<\/sup> American College of Radiology <\/i>(<\/i>2022<\/i>)<\/i>.<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

\u00a0<\/p>\n

<\/div>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SINGAPORE<\/span><\/span>, Feb. 5, 2025<\/span><\/span> \/PRNewswire\/ — Asia<\/span> is the region most impacted by lung cancer, accounting for 63.1% of newly diagnosed lung cancers and 62.9% of lung cancer deaths worldwide(1)<\/sup>.<\/p>\n

Many countries have applied low-dose CT scans to screen for this deadly cancer to improve early detection and treatment outcomes. However, only the highest-risk population (heavy smokers) is advised to undergo low-dose CT scans routinely to minimize the risk of radiation-induced cancer during scanning rounds(2)<\/sup>. Moreover, CT devices are not easily accessible for many people due to geographical and economic barriers.<\/p>\n

Due to these limitations, multiple studies have pointed out surprising data: the current screening guidelines and eligibility criteria may miss over 50% of lung cancer cases in never-smokers(3)<\/sup>; women are particularly vulnerable, with 83% of women in South-East Asia<\/span> with lung cancer being never-smokers(4)<\/sup>; non-smokers are diagnosed at a later stage than smokers (5)<\/sup>; and about a third of lung cancer deaths occur in non-smokers(6)<\/sup>.<\/p>\n

New screening method leveraging AI and genomics technology advantages<\/b>\u00a0<\/p>\n

SPOT-MAS is a blood test developed by Gene Solutions to detect multiple features of circulating tumor DNA (ctDNA) released from cancer cells, indicating if someone may have cancer. Previously, SPOT-MAS was validated as a multi-cancer early detection test in a longitudinal study involving 9,024 healthy people. While detecting multiple cancers, including lung cancer, in a single blood test is an aspirational goal, the key challenge lies in making it affordable for a large population.<\/p>\n

To address this challenge, Gene Solutions integrates a multiomics tumor ATLAS with AI-driven feature engineering and deep learning models<\/a>\u00a0to analyze genetic, epigenetic, and fragmentomic data. This methodology offers a precise, non-invasive, and affordable test specifically designed for lung cancer screening. Through enhanced AI analysis and the incorporation of lung-specific features, the SPOT-MAS Lung test has demonstrated remarkable effectiveness, achieving 90% sensitivity and 92% specificity(7)<\/sup>.<\/p>\n

A new hope for lung cancer burden in Asia<\/span><\/b><\/p>\n

With extensive connections to healthcare providers across Asia<\/span>, Gene Solutions aims to introduce this smart blood test to clinical practice in early 2025 to support the urgent need for accessible lung screening. In the long run, a convenient and precise test like SPOT-MAS can increase the chances of early detection for at-risk populations and potentially reduce the mortality rate associated with late diagnoses.<\/p>\n

Furthermore, ctDNA screening tests can serve as a companion tool to low-dose CT scans<\/span><\/a>.\u00a0<\/span>In real-life practice, many CT scans yield ambiguous results, such as small lung nodules classified under LUNG-RADS (8)<\/sup>, which might leave clinicians and patients uncertain about the malignancy status and the appropriate follow-up surveillance path. ctDNA screening results can thus support and guide diagnosis and surveillance strategies.<\/p>\n

At the January\u00a0event Personalized cancer care in Asia<\/span>: Advancing Genomics & AI in Singapore<\/span>, Dr. Nguyen Hoai Nghia<\/span>, Founder of Gene Solutions,\u00a0highlighted: “This technology represents a paradigm shift in lung cancer screening, particularly for underserved\u00a0populations.<\/b> By harnessing the power of ctDNA and AI, we aim to make blood-based cancer screening tests more accurate and more affordable, hence support more early detection and effective treatment outcomes.”\u00a0<\/p>\n

\n

Dr. Nguyen Hoai Nghia announced the performance of the SPOT-MAS Lung test at the event \"Personalized Cancer Care in Asia: Advancing Genomics & AI\" at SGX Auditorium, Singapore, January 2025.<\/a>
Dr. Nguyen Hoai Nghia announced the performance of the SPOT-MAS Lung test at the event “Personalized Cancer Care in Asia: Advancing Genomics & AI” at SGX Auditorium, Singapore, January 2025.<\/span><\/p>\n<\/div>\n

About\u00a0Gene Solutions
<\/b>Gene Solutions, a pioneering biotech company in Asia<\/span>, is leading the way in leveraging advanced AI and ctDNA technologies for innovative cancer detection solutions. The company partners with over 4,500 hospitals and clinics across Southeast Asia<\/span> and boasts a team of approximately 250 biology experts and technicians out of a total of 700 employees. Gene Solutions has published more than 50 peer-reviewed publications and conducted over 50 multi-center studies across the region. The company, recognized for its proprietary research and CAP-accredited laboratories in Singapore<\/span> and Vietnam<\/span>, combines multi-dimensional genomics with AI-driven approaches to transform cancer care.\u00a0<\/p>\n

For media inquiries, please contact: Gene Solutions Media Contact\u00a0
Ms. Emma Ngo<\/span><\/b>\u00a0
www.genesolutions.com<\/a><\/u>\u00a0
Email: pr@genesolutions.com<\/a><\/b>\u00a0<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

References:<\/b>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(1)<\/sup> <\/i>Chiu, C., & Yang, P. (2024). Challenges of lung cancer control in Asia. EClinicalMedicine, 74, 102706. doi.org\/10.1016\/j.eclinm.2024.102706<\/i>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(2)<\/sup> <\/i>Pozzessere, C.; von Garnier, C.; Beigelman-Aubry, C. Radiation Exposure to Low-Dose Computed Tomography for Lung Cancer Screening: Should We Be Concerned? Tomography 2023, 9, 166-177. doi.org\/10.3390\/tomography9010015<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(3)<\/sup> <\/i>Kerpel-Fronius, A., Tammem\u00e4gi, M., Cavic, M., Henschke, C., Jiang, L., Kazerooni, E., Lee, C., Ventura, L., Yang, D., Lam, S., Huber, R. M., Yang, D., Zulueta, J., Viola, L., Mohan, A., Lee, C., Cavic, M., Schmidt, H., Kazerooni, E., . . . Huber, R. (2021). Screening for lung cancer in Individuals who Never smoked: An International Association for the Study of Lung Cancer Early Detection and Screening Committee report. Journal of Thoracic Oncology, 17(1), 56\u201366. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.031<\/a><\/u><\/i>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(4)<\/sup> <\/i>Barta, J. A., Powell, C. A., & Wisnivesky, J. P. (2019). Global Epidemiology of Lung Cancer. Annals of Global Health, 85(1). https:\/\/doi.org\/10.5334\/aogh.2419<\/i>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(5)<\/sup> Barta JA, et al. Global Epidemiology of Lung Cancer. Annals of Global Health. (2019). 85(1): 8, 1\u201316. DOI: https:\/\/doi. org\/10.5334\/aogh.2419<\/i>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(6)<\/i><\/sup>\u00a0GLOBOCAN (2020).\u00a0<\/i>\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(7)<\/sup> Nguyen, Van Thien Chi et al. Cost-Effective Shallow Genome-Wide Sequencing for Profiling Plasma cfDNA Signatures to Enhance Lung Cancer Detection (January 11, 2025). dx.doi.org\/10.2139\/ssrn.5094108<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

(<\/i>8<\/i><\/sup>)<\/sup> American College of Radiology <\/i>(<\/i>2022<\/i>)<\/i>.<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

\u00a0<\/p>\n

<\/div>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-17627","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/17627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17627"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/17627\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}